Master Regulator Analysis in Breast Cancer Patients
Master regulator analysis to prioritize treatment of residual disease following neoadjuvant chemotherapy for breast cancer in patient-derived tumor xenografts
Determine whether master regulator-directed therapy will demonstrate a greater reduction of tumor growth in patient-derived xenografts from tumors resistant to neoadjuvant taxane therapy [i.e. paclitaxel or docetaxel +/- adriamycin/cytoxan] as compared to taxane (i.e. control).
Are you Eligible? (Inclusion Criteria)
Patients with breast cancer who have been treated with standard neoadjuvant chemotherapy who fail to have a complete response prior to surgery.